Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Bradycardia Article
This is a selection made from among articles on Drug Treatment Bradycardia. For a permanent link to this article, or to bookmark it for future reading, click here.
Drug Addiction and Pregnancy
from:When a woman is struggling with drug addiction during her pregnancy, that drug use affects more than just her – it affects her fetus as well. The drugs can also have devastating effects on the child one he or she is born. Drug addiction and pregnancy should be treated as a very serious issue.
A mother taking illegal drugs during pregnancy increases her risk for anemia, blood and heart infections, skin infections, hepatitis, and other infectious diseases. She also is at greater risk for sexually transmitted diseases. Most drugs cross the placenta – the organ that provides nourishment to the baby. Some can cause direct toxic, or poisonous effets and create a child who is born with a drug addiction.
During pregnancy, a woman needs to take active steps to combat her drug addiction, if not for herself, but for the good of her unborn child. While most drugs don’t necessarily cause deformities, what they can do is stunt the growth of the child leading to low birth weight and having a baby born already addicted to drugs.
Once that child takes his or her first breath, they begin the painful process of withdrawing from drugs. This puts stress on the baby’s organs and provides for a very unhappy life. As much pain as an adult goes through during withdrawal, the pain is compounded for a helpless child.
A urine lab test performed on a woman during her pregnancy called a chromatography can detect the presence of many drugs including marijuana and cocaine. Marijuana use during pregnancy is linked to behavioral problems in the child and cocaine can bring on premature delivery and even stillbirth.
Drug addiction is a very complex mental condition as well a physical one. During pregnancy, it becomes a serious health risk both for the mother and the baby. After birth, you may find yourself having troubles coping with the stress of a newborn. You may have difficulty dealing with your baby’s needs such as feeding and diapering.
So what can you do if you are dealing with drug addiction during pregnancy? This can be problematic, especially if the child is not planned. The best thing you can do is to stop using drugs immediately. Sure, this will cause severe physical symptoms, but those generally subside within a few weeks. Get yourself into some type of treatment program and get counseling.
A pregnancy is exciting, but when you are struggling with drug addiction, it can be painful. You owe it to yourself and you owe it to your child to beat your drug addiction and have a healthy pregnancy.
Drug Treatment Bradycardia Specific links
Drug Treatment Bradycardia News
Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices ... - MarketWatch (press release)
 Medgadget.com | Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices ... MarketWatch (press release) Pacemakers are designed to treat bradycardia, a condition in which the heart beats too slowly - usually less than 60 beats per minute - depriving the body of sufficient oxygen. The INGENIO and ADVANTIO pacemakers feature RightRate(TM) pacing technology ... Boston Scientific (BSX) Gets FDA Approval for INGENIO, ADVANTIO, and INVIVE |
FDA Issues Multiple Sclerosis Drug Alert - U.S. News & World Report
 InPharm | FDA Issues Multiple Sclerosis Drug Alert U.S. News & World Report Who develop severe bradycardia after receiving the first dose of Gilenya. With certain pre-existing conditions in whom bradycardia may be poorly tolerated. Receiving therapy with other drugs that slow the heart rate or electrical impulses that regulate ... FDA: MS drug fingolimod gets CVD warnings Cardiovascular Monitoring With Gilenya Gilenya to stay on US market – but with new safety warnings |
FDA OKs Boston Scientific's New Line of Pacemakers - Fox Business
Medgadget.com | FDA OKs Boston Scientific's New Line of Pacemakers Fox Business By Jennifer Booton US officials gave the green light Monday to Boston Scientific's (BSX) new line of pacemakers used to treat bradycardia, a condition in which the heart beats too slowly. The drug giant received the OK by the Food and Drug ... Boston Scientific plans global expansion |
FDA issues multiple sclerosis drug alert - Medical Xpress
 RTT News | FDA issues multiple sclerosis drug alert Medical Xpress Who develop severe bradycardia after receiving the first dose of Gilenya. With certain pre-existing conditions in whom bradycardia may be poorly tolerated. Receiving therapy with other drugs that slow the heart rate or electrical impulses that regulate ... FDA completes evaluation of patient death after first dose of Gilenya |
Two New S1P Receptor Modulators Pass Phase 2 Test in MS - Medscape
Two New S1P Receptor Modulators Pass Phase 2 Test in MS Medscape However, both were still associated with cardiovascular effects, such as bradycardia. Fingolimod, the first oral agent approved for use in MS, is an effective treatment, but some concerns about cardiovascular effects, particularly bradycardia and ... |
Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR ... - Reuters
Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR ... Reuters Patients with cardiac disease and/or risk factors for bradycardia need to be closely monitored. Caution is to be exercised in patients who have or may develop QT prolongation. Hypokalemia or hypomagnesemia must be corrected prior to initiating therapy ... |
Shire to Present Scientific Data Across Range of Psychiatric Disorders at ... - MarketWatch (press release)
Shire to Present Scientific Data Across Range of Psychiatric Disorders at ... MarketWatch (press release) Stimulants, such as amphetamines and methylphenidates, are subject to misuse, abuse, addiction, and criminal diversion. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events. INTUNIV is indicated for the treatment of ... |
News in Brief: Week of May 21-25 - AAFP News Now
News in Brief: Week of May 21-25 AAFP News Now By News Staff The CDC is reiterating its stance on the use of so-called single-dose or single-use drug vials, stressing that these products should be administered to only one patient. According to the agency, these medication formulations typically ... |
Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated ... - MarketWatch (press release)
Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated ... MarketWatch (press release) Of that total, the Company estimates that approximately 130000 are diagnosed with RDS and nearly 90000 are treated with surfactant replacement therapy. On March 6, 2012, Discovery Labs announced that the US Food and Drug Administration (FDA) approved ... |
Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated ... - PR Newswire (press release)
Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated ... PR Newswire (press release) WARRINGTON, Pa., May 1, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with ... |